| Disease-specific alterations in the enteric virome in inflammatory bowel disease JM Norman, SA Handley, MT Baldridge, L Droit, CY Liu, BC Keller, ... Cell 160 (3), 447-460, 2015 | 1245 | 2015 |
| A defined commensal consortium elicits CD8 T cells and anti-cancer immunity T Tanoue, S Morita, DR Plichta, AN Skelly, W Suda, Y Sugiura, ... Nature 565 (7741), 600-605, 2019 | 908 | 2019 |
| Altered virome and bacterial microbiome in human immunodeficiency virus-associated acquired immunodeficiency syndrome CL Monaco, DB Gootenberg, G Zhao, SA Handley, MS Ghebremichael, ... Cell host & microbe 19 (3), 311-322, 2016 | 414 | 2016 |
| Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense KG Lassen, P Kuballa, KL Conway, KK Patel, CE Becker, JM Peloquin, ... Proceedings of the National Academy of Sciences 111 (21), 7741-7746, 2014 | 402 | 2014 |
| Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity TJ Nice, MT Baldridge, BT McCune, JM Norman, HM Lazear, M Artyomov, ... Science 347 (6219), 269-273, 2015 | 373 | 2015 |
| Kingdom-agnostic metagenomics and the importance of complete characterization of enteric microbial communities JM Norman, SA Handley, HW Virgin Gastroenterology 146 (6), 1459-1469, 2014 | 206 | 2014 |
| The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells JM Norman, M Mashiba, LA McNamara, A Onafuwa-Nuga, E Chiari-Fort, ... Nature immunology 12 (10), 975-983, 2011 | 115 | 2011 |
| Computer-guided design of optimal microbial consortia for immune system modulation RR Stein, T Tanoue, RL Szabady, SK Bhattarai, B Olle, JM Norman, ... Elife 7, e30916, 2018 | 74 | 2018 |
| Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers M Dsouza, R Menon, E Crossette, SK Bhattarai, J Schneider, YG Kim, ... Cell Host & Microbe 30 (4), 583-598. e8, 2022 | 71 | 2022 |
| VE303, a defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: a randomized clinical trial T Louie, Y Golan, S Khanna, D Bobilev, N Erpelding, C Fratazzi, M Carini, ... Jama 329 (16), 1356-1366, 2023 | 67 | 2023 |
| ADP ribosylation factor 1 activity is required to recruit AP-1 to the major histocompatibility complex class I (MHC-I) cytoplasmic tail and disrupt MHC-I trafficking in HIV-1 … ER Wonderlich, JA Leonard, DA Kulpa, KE Leopold, JM Norman, ... Journal of virology 85 (23), 12216-12226, 2011 | 35 | 2011 |
| Identification of trypsin-degrading commensals in the large intestine Y Li, E Watanabe, Y Kawashima, DR Plichta, Z Wang, M Ujike, QY Ang, ... Nature 609 (7927), 582-589, 2022 | 28 | 2022 |
| Treatment of clostridium difficile infection J Schneider, Y Kim, B Olle, S Reddy, J Norman, J Patarroyo US Patent 9,999,641, 2018 | 28 | 2018 |
| Fecal microbiota transplantation influences procarcinogenic Escherichia coli in recipient recurrent Clostridioides difficile patients S Nooij, QR Ducarmon, JFJ Laros, RD Zwittink, JM Norman, WK Smits, ... Gastroenterology 161 (4), 1218-1228. e5, 2021 | 24 | 2021 |
| Increased diversity of gut microbiota during active oral immunotherapy in peanut allergic adults Z He, VLG Vadali, RL Szabady, W Zhang, JM Norman, B Roberts, ... Allergy 76 (3), 927, 2021 | 17 | 2021 |
| 1953. VE303, a Rationally Designed Bacterial Consortium for Prevention of Recurrent Clostridioides difficile (C. Difficile) infection (rCDI), Stably Restores the Gut … D Bobilev, S Bhattarai, R Menon, B Klein, S Reddy, B Olle, B Roberts, ... Open Forum Infectious Diseases 6 (Supplement_2), S60-S60, 2019 | 16 | 2019 |
| Treatment of Clostridium difficile infection J Schneider, Y Kim, B Olle, S Reddy, J Norman, J Patarroyo US Patent 10,064,904, 2018 | 12 | 2018 |
| Treatment of clostridium difficile infection J Schneider, Y Kim, B Olle, S Reddy, J Norman, J Patarroyo US Patent 10,350,250, 2019 | 11 | 2019 |
| Treatment of clostridium difficile infection J Schneider, Y Kim, B Olle, S Reddy, J Norman, J Patarroyo US Patent 10,456,431, 2019 | 10 | 2019 |
| Randomized, double-blind, placebo (PBO)-controlled, single-and multiple-dose phase 1 study of VE202, a defined bacterial consortium for treatment of IBD: safety and … J Silber, J Norman, T Kanno, E Crossette, R Szabady, R Menon, M Marko, ... Inflammatory Bowel Diseases 28 (Supplement_1), S65-S66, 2022 | 8 | 2022 |
Herbert W. VirginWashington University School of Medicine在 wustl.edu 的电子邮件经过验证
